{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:04:28Z","timestamp":1787871868274,"version":"build-2784847793"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N95023D00001"],"award-info":[{"award-number":["75N95023D00001"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>We applied a target trial emulation framework to estimate the association between early and delayed initiation of remdesivir (RDV) with mortality in hospitalized adults between May 1, 2020, and July 31, 2024, with varying coronavirus disease 2019 (COVID-19) clinical severity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using electronic health records in the National COVID Cohort Collaborative (N3C) database, we emulated a sequence of randomized target trials initiated on each of the first 7 days of hospitalization. We identified 373 226 eligible person-trial hospitalizations, of which 53 959 were initiators and 319 267 were noninitiators of RDV treatment. Patients were divided into clinical severity subgroups based on baseline oxygenation, which included no supplemental oxygen (NSO), noninvasive supplemental oxygen (NISO), or invasive ventilation (IV). In each trial, initiators were matched with replacement to noninitiators receiving the same oxygenation type. Trials beginning on days 1\u20133 and days 4\u20137 of hospitalization were pooled separately to evaluate the effects of early and delayed initiation of RDV, respectively. Cox proportional hazards regression was used to estimate the marginal hazard ratio for mortality between initiators and noninitiators within each treatment delay.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Across trials, 53 449 initiators were matched to 26 600 unique noninitiators. Early, but not delayed, RDV treatment was associated with a reduction in 60-day mortality in the NSO (hazard ratio [HR], 0.89; 95% CI, 0.84\u20130.95) and NISO subgroups (HR, 0.91; 95% CI, 0.84\u20130.99), but not in those receiving IV. Results were consistent across sensitivity analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Early treatment with RDV is associated with reduced mortality risk in hospitalized COVID-19 patients either not on supplemental oxygen or receiving noninvasive supplemental oxygen.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae740","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T21:03:39Z","timestamp":1741122219000},"source":"Crossref","is-referenced-by-count":2,"title":["Effect of Early and Delayed Treatment With Remdesivir on Mortality in Patients Hospitalized With COVID-19"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-2472","authenticated-orcid":false,"given":"Steve R","family":"Makkar","sequence":"first","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]},{"name":"Nextonic Solutions , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7399-7911","authenticated-orcid":false,"given":"Kristen","family":"Hansen","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]},{"name":"Axle Research and Technologies , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8423-6464","authenticated-orcid":false,"given":"Nathan","family":"Hotaling","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]},{"name":"Axle Research and Technologies , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2633-8459","authenticated-orcid":false,"given":"Andrew","family":"Toler","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]},{"name":"Axle Research and Technologies , Rockville, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3532-4809","authenticated-orcid":false,"given":"Hythem","family":"Sidky","sequence":"additional","affiliation":[{"name":"National Center for Advancing Translational Sciences, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"key":"2025030419135524000_ofae740-B1","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","article-title":"Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses","volume":"399","author":"WHO Solidarity Trial Consortium","year":"2022","journal-title":"Lancet"},{"key":"2025030419135524000_ofae740-B2","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"2025030419135524000_ofae740-B3","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of COVID-19\u2014final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"2025030419135524000_ofae740-B4","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"2025030419135524000_ofae740-B5","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1473-3099(21)00485-0","article-title":"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial","volume":"22","author":"Ader","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2025030419135524000_ofae740-B6","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.4103\/ija.IJA_149_21","article-title":"Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: a prospective randomised study","volume":"65","author":"Mahajan","year":"2021","journal-title":"Indian J Anaesth"},{"key":"2025030419135524000_ofae740-B7","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1093\/jac\/dkaa321","article-title":"Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU","volume":"75","author":"Pasquini","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025030419135524000_ofae740-B8","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofad482","article-title":"Remdesivir is associated with reduced mortality in COVID-19 patients requiring supplemental oxygen including invasive mechanical ventilation across SARS-CoV-2 variants","volume":"10","author":"Mozaffari","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025030419135524000_ofae740-B9","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1093\/cid\/ciab875","article-title":"Remdesivir treatment in hospitalized patients with coronavirus disease 2019 (COVID-19): a comparative analysis of in-hospital all-cause mortality in a large multicenter observational cohort","volume":"75","author":"Mozaffari","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025030419135524000_ofae740-B10","doi-asserted-by":"crossref","first-page":"e2244505","DOI":"10.1001\/jamanetworkopen.2022.44505","article-title":"Association of remdesivir treatment with mortality among hospitalized adults with COVID-19 in the United States","volume":"5","author":"Chokkalingam","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025030419135524000_ofae740-B11","doi-asserted-by":"crossref","first-page":"XXX\u2013XX","DOI":"10.1093\/ofid\/ofab278","article-title":"Remdesivir versus standard-of-care for severe coronavirus disease 2019 infection: an analysis of 28-day mortality","volume":"8","author":"Olender","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2025030419135524000_ofae740-B12","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1093\/cid\/ciab698","article-title":"Remdesivir and mortality in patients with coronavirus disease 2019","volume":"74","author":"Diaz","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025030419135524000_ofae740-B13","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"2025030419135524000_ofae740-B14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12874-023-02000-9","article-title":"Implementation of the trial emulation approach in medical research: a scoping review","volume":"23","author":"Scola","year":"2023","journal-title":"BMC Med Res Methodol"},{"key":"2025030419135524000_ofae740-B15","article-title":"Remdesivir quick point-of-care reference","author":"Infectious Disease Society of America","year":"2022"},{"key":"2025030419135524000_ofae740-B16","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/cid\/ciab631","article-title":"Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with coronavirus disease 2019 (COVID-19)","volume":"74","author":"Wong","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025030419135524000_ofae740-B17","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1093\/jac\/dkab321","article-title":"Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19","volume":"76","author":"Garcia-Vidal","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025030419135524000_ofae740-B18","doi-asserted-by":"crossref","first-page":"e282","DOI":"10.1097\/IPC.0000000000001023","article-title":"Early use of remdesivir in patients hospitalized with COVID-19 improves clinical outcomes: a retrospective observational study","volume":"29","author":"Paranjape","year":"2021","journal-title":"Infect Dis Clin Pract"},{"key":"2025030419135524000_ofae740-B19","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1002\/sim.8533","article-title":"Matching with time-dependent treatments: a review and look forward","volume":"39","author":"Thomas","year":"2020","journal-title":"Stat Med"},{"key":"2025030419135524000_ofae740-B20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/jamia\/ocaa196","article-title":"The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment","volume":"28","author":"Haendel","year":"2021","journal-title":"J Am Med Inform Assoc"},{"key":"2025030419135524000_ofae740-B21","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.15585\/mmwr.mm7240a3","article-title":"COVID-19-associated hospitalizations among U.S. adults aged (65 years\u2014COVID-NET, 13 states, January\u2013August 2023","volume":"72","author":"Taylor","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025030419135524000_ofae740-B22","doi-asserted-by":"publisher","DOI":"10.1101\/2021.10.04.21264513","article-title":"Use of an EHR to inform an administrative data algorithm to categorize inpatient COVID-19 severity","volume-title":"medRxiv","author":"Garry","year":"2021"},{"key":"2025030419135524000_ofae740-B23","doi-asserted-by":"crossref","first-page":"e213071","DOI":"10.1001\/jamanetworkopen.2021.3071","article-title":"Comparison of time to clinical improvement with vs without remdesivir treatment in hospitalized patients with COVID-19","volume":"4","author":"Garibaldi","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2025030419135524000_ofae740-B24","doi-asserted-by":"crossref","first-page":"e015735","DOI":"10.1136\/bmjopen-2016-015735","article-title":"Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans","volume":"7","author":"Xie","year":"2017","journal-title":"BMJ Open"},{"key":"2025030419135524000_ofae740-B25","doi-asserted-by":"crossref","DOI":"10.1093\/acprof:oso\/9780195152968.001.0001","volume-title":"Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence","author":"Singer","year":"2003"},{"key":"2025030419135524000_ofae740-B26","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12874-022-01679-6","article-title":"Survival prediction models: an introduction to discrete-time modeling","volume":"22","author":"Suresh","year":"2022","journal-title":"BMC Med Res Methodol"},{"key":"2025030419135524000_ofae740-B27","first-page":"155","article-title":"It's about time: using discrete-time survival analysis to study duration and the timing of events","volume":"18","author":"Singer","year":"1993","journal-title":"J Educ Behav Stat"},{"key":"2025030419135524000_ofae740-B28","doi-asserted-by":"crossref","DOI":"10.1002\/9781119030638","volume-title":"Causality in a Social World: Moderation, Meditation and Spill-over","author":"Hong","year":"2015"},{"key":"2025030419135524000_ofae740-B29","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/sim.8502","article-title":"Variance estimation when using propensity-score matching with replacement with survival or time-to-event outcomes","volume":"39","author":"Austin","year":"2020","journal-title":"Stat Med"},{"key":"2025030419135524000_ofae740-B30","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"2025030419135524000_ofae740-B31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1214\/09-STS313","article-title":"Matching methods for causal inference: a review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Stat Sci"},{"key":"2025030419135524000_ofae740-B32","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s15010-022-01850-7","article-title":"Is remdesivir safe in patients with renal impairment? Experience at a large tertiary urban medical center","volume":"51","author":"Sunny","year":"2023","journal-title":"Infection"},{"key":"2025030419135524000_ofae740-B33","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(22)00528-8","article-title":"Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials","volume":"11","author":"Amstutz","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2025030419135524000_ofae740-B34","doi-asserted-by":"crossref","first-page":"e28168","DOI":"10.1002\/jmv.28168","article-title":"Effectiveness of remdesivir with corticosteroids for COVID-19 patients in intensive care unit: a hospital-based observational study","volume":"95","author":"Hanafusa","year":"2023","journal-title":"J Med Virol"},{"key":"2025030419135524000_ofae740-B35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijid.2021.02.092","article-title":"A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: a real-world analysis","volume":"106","author":"Mehta","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2025030419135524000_ofae740-B36","first-page":"1305","article-title":"Time lag between COVID-19 diagnosis and symptoms onset for different population groups: evidence that self-testing in schools was associated with timely diagnosis among children","volume":"12","author":"Mellou","year":"2022","journal-title":"Life (Basel)"},{"key":"2025030419135524000_ofae740-B37","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.cmi.2022.04.018","article-title":"Remdesivir for the treatment of COVID-19: a systematic review and meta-analysis","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2025030419135524000_ofae740-B38","doi-asserted-by":"crossref","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"L\u00e9vesque","year":"2010","journal-title":"BMJ"},{"key":"2025030419135524000_ofae740-B39","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/EDE.0000000000001601","article-title":"Emulating target trials to avoid immortal time bias\u2014an application to antibiotic initiation and preterm delivery","volume":"34","author":"Caniglia","year":"2023","journal-title":"Epidemiology"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/2\/ofae740\/62194084\/ofae740.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/2\/ofae740\/62194084\/ofae740.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T21:03:50Z","timestamp":1741122230000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae740\/8044895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1,31]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae740","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,1,31]]},"article-number":"ofae740"}}